Markers of bone and collagen metabolism - problems and perspectives in paediatrics

Hormone Research in Paediatrics

Volumn 48, Issue 5, 1997, Pages 50-59

  Schönau, Eckhard ^a   Rauch, F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bone disorders; Bone markers; Bone turnover; Collagen markers; Growth; Osteogenesis imperfecta

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; COLLAGEN TYPE 1; GLYCOSIDE; HYDROXYLYSINE; HYDROXYPROLINE; MARKER; OSTEOCALCIN; PEPTIDE; PROCOLLAGEN; PYRIDINOLINE;

AGE; BIOCHEMISTRY; BODY HEIGHT; BONE METABOLISM; CIRCADIAN RHYTHM; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONFERENCE PAPER; DIET; GROWTH RATE; HUMAN; HYDROXYPROLINE URINE LEVEL; KIDNEY CLEARANCE; LIVER FUNCTION; OSSIFICATION; OSTEOBLAST; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PUBERTY; SEX DIFFERENCE; URINALYSIS;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DEVELOPMENT; CHILD; COLLAGEN; HUMANS;

EID: 1842407854     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000191329     Document Type: Article

References (34)

1. Calvo MS, Eyre DR, Grundberg CM: Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996: 17:333-368.
2. Eriksen EF, Brixen K, Charles P: New markers of bone metabolism: clinical use in metabolic disease. Eur J Endoerinol 1995:132:251-263.
3. Dclntas PD: Biochemical markers of bone turnover. Acta Orthop Scand 1995;66(suppl 266): 176-182.
4. Risteli L, Risteli J: Biochemical markers of bone metabolism. Ann Med 1993:25:385-393.
5. Frost HM: Bone development during childhood: in Schónau E (ed): Paediatric Osteology: New Developments in Diagnosis and Therapy. Amsterdam. Elsevier. 1996. pp 3-43.
6. Lowell DS, Dean DD: The biology, chemistry and biochemistry of the mammalian growth plate; in Coc FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York. Raven Press, 1992. pp 313-355.
7. Dempster DW: Bone remodelling; in Coc FL. Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York. Raven Press. 1992. pp 355-383.
8. Baron RE: Anatomy and ultrastructure of bone; in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York, Lippincott-Ravcn, 1996. pp 3-11.
9. Eyre DR: The specificity of collagen cross-links as marker of bone and connective tissue degradation. Acta Orthop Scand 1995;66(suppl 266): 166-170.
10. Stein GS, Lian JB, Owen TA: Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEBJ 1990:4:3111-3123.
11. Van Hoof VO. De Broe ME: Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 1994:31:197-293.
12. Van Hoof VO, Lepoutre LC, Hoylaerts MF, Chcvigne R, De Broc ME: Improved agarose electrophoretic method for separating alkaline phosphatase isoenzymes in scrum. Clin Chem 1988:34:1857-1862.
13. Gomez B, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Danilof TGY, Rung VT: Monoclonal antibody assay for measurement bone-specific alkaline phosphatase activity in serum. Clin Chem 1995:41:1560-1566.
14. Panigrahi K, Delmas PD, Singer F, Rayn W, Reiss W, Fisher R, Miller PD, Mizrahi I, Dartc C, Kress BC, Christenson RJ: Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994;40:822-828.
15. Ducv P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G: Increased bone formation in osteocalcin-deficient mice. Nature 1996:382:448-452.
16. Masters PW, Jones RG, Purves DA, Cooper JM: Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994:40:358-363.
17. Ristcli J, Ristcli L: Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995;22(suppl 2):77-81.
18. Govcrde BC, Vecnkamp FJN: Routine assay of total urinary hydroxyproline based on resin-catalvscd hydrolysis. Clin Chem Acta 1972:41: 29-40.
19. Dawson CD, Jewell S, Driskell WJ: Liquid-chromatographic determination of total hydroxyproline in urine. Clin Chem 1988:34: 1572-1574.
20. Eyre DR: Cross-linking in collagen and elaslin. Ann Rev Biochcm 1984:53:717-748.
21. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR: A specific immunoassay for monitoring human bone resorption: quantification of type 1 collagen cross-linked N-telopeptidcs in urine. J Bone Miner Res 1992:7:1251-1258.
22. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C: Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994:40:2022-2025.
23. Bettica P, Baylink DJ, Moro L: Galactosyl hy-droxylysine and dcoxypyridinoline: A methodological comparison. Eur J Clin Chem Clin Biochem 1993:31:459-465.
24. Rauch F, Schnabel D, Seibel MJ, Remer T, Stabrey A, Michalk D, Schönau E: Urinary excretion of galactosyl-hydroxylysinc is a marker of growth in children. J Clin Endocrinol Metab 1995;80:1295-1300.
25. Saggese G, Baroncelli GI, Bertelloni S, Cin-quanla L, Di Nero G: Twenty- four-hour osteocalcin, carboxvterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagcn rhythms in normal and growth-retarded children. Pediatr Res 1994:35: 409-415.
26. Fujimoto S, Kubo T, Tanaka H, Miura M, Sei-no Y: Urinary pyridinoline and deoxvpyridi-noline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab 1995;80:1922-1928.
27. Delmas PD, Châtelain P, Malaval L, Bonne G: Serum bone GLA-protein in growth hormone deficient children. J Bone Miner Res 1986:1: 333-338.
28. Johansen JS, Jensen SB, Riis BJ. Rasmussen R, Zachmann M, Christiansen C: Serum bone GLA protein: A potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab 1990:71: 122-126.
29. Saggese G, Baroncclli GI, Bertelloni S, Cin-quanta L, Di Nero G: Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993; 122:37-45.
30. Kruse K, Kracht U: Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur J Pediatr 1986;145:27-33.
31. Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM: Serum concentrations of procollagcn I C-tcrminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lcthai osteogenesis imperfecta. Acta Paediatr 1993:82:764-767.
32. Canalis E: Clinical review 83. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996:81:3441-3447.
33. Hyams JS, Moore RE, Leichtner AM, Carey DE, Goldberg BD: Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988:112:893-898.
34. Birkebæk NH, Exberg G, Andersen K, Wol-thers O, Hassanger C: Bone and collagen turnover during treatment with inhaled dry powder budcsonidc and bcclomcthasone dipropionate. Arch Dis Child 1995:73:524-527.